NCT03305913View on ClinicalTrials.gov

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

April 26, 2019

Conditions
Pretreated Metastatic Colorectal Cancer
Interventions
DRUG

TAS 102

TAS-102 tablet

DRUG

Regorafenib

Regorafenib tablet

Trial Locations (1)

55131

Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Mainz

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH

UNKNOWN

collaborator

Bayer

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT03305913 - Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy | Biotech Hunter | Biotech Hunter